<doc>
  <docmeta id="113hres161ih">
    <bill congress="113" type="hres" number="161" version="ih"/>
    <revision size="3059" annotations="0" id="8" commit-time="2013-04-17T17:11:09+00:00" committer="favila" doc="113hres161ih/8.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <resolution xmlns:cato="http://namespaces.cato.org/catoxml" dms-id="HD087D001E6DD4B0AB713AE943B722049" key="H" public-private="public" resolution-stage="Introduced-in-House" resolution-type="house-resolution" star-print="no-star-print">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HRES 161 IH: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-04-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">IV</distribution-code>
		<congress display="yes">113th CONGRESS</congress>
		<session display="yes">1st Session</session>
		<legis-num>H. RES. 161</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action display="yes">
			<action-date date="20130415">April 15, 2013</action-date>
			<action-desc>
        <sponsor name-id="R000395">Mr. Rogers of
			 Kentucky</sponsor> (for himself, <cosponsor name-id="K000375">Mr.
			 Keating</cosponsor>, <cosponsor name-id="W000672">Mr. Wolf</cosponsor>,
			 <cosponsor name-id="R000011">Mr. Rahall</cosponsor>,
			 <cosponsor name-id="G000569">Mr. Grimm</cosponsor>,
			 <cosponsor name-id="L000562">Mr. Lynch</cosponsor>,
			 <cosponsor name-id="T000266">Mr. Tierney</cosponsor>, and
			 <cosponsor name-id="A000055">Mr. Aderholt</cosponsor>) submitted the following
			 resolution; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>RESOLUTION</legis-type>
		<official-title display="yes">Expressing the sense of the House of
		  Representatives that the Food and Drug Administration should encourage the use
		  of abuse-deterrent formulations of drugs.</official-title>
	</form>
	<preamble>
		<whereas>
      <text>Whereas when abuse-deterrent formulations of a drug have
			 been developed, approved, and recognized as effective by the <cato:entity-ref entity-type="federal-body" entity-id="7524">Food and Drug
			 Administration,</cato:entity-ref> the approval and marketing of generic versions that do not have
			 abuse-deterrent features are likely to prevent achievement of the public health
			 purposes of the efforts to develop such abuse-deterrent formulations;</text>
		</whereas>
    <whereas>
      <text>Whereas the <cato:entity-ref entity-type="federal-body" entity-id="1127">Office of National Drug Control Policy</cato:entity-ref> and the
			 <cato:entity-ref entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> have for many years strongly encouraged
			 manufacturers of opioid drug products to develop abuse-deterrent formulations
			 designed to prevent or discourage the abuse or misuse of those products;</text>
		</whereas>
    <whereas>
      <text>Whereas in response, several opioid drug manufacturers
			 have developed abuse-deterrent formulations;</text>
		</whereas>
    <whereas>
      <text>Whereas helping to reduce the level of abuse of opioid
			 drug products is dependent on the widespread adoption of new technologies and
			 approaches to the safer formulation of these drugs;</text>
		</whereas>
    <whereas>
      <text>Whereas the <cato:entity-ref entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref> has
			 acknowledged that the <cato:entity-ref entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has the authority under
			 current law to require generic versions of products that have been formulated
			 or reformulated with abuse-deterrent features to have comparable features;
			 and</text>
		</whereas>
    <whereas>
      <text>Whereas fourteen Members of Congress in a bipartisan
			 coalition have cosponsored the <cato:entity-ref entity-type="act" value="Stop Tampering with Prescription Pills (STOPP) Act">Stop Tampering with Prescription Pills (STOPP)
			 Act</cato:entity-ref>, which would similarly promote abuse-deterrent technologies in addictive
			 painkillers: Now, therefore, be it</text>
		</whereas>
  </preamble>
	<resolution-body id="H2DE0AC357441414DBB2533926F9A8FC9" style="traditional">
		<section display-inline="yes-display-inline" id="HCD89C54105B741709347FB2FF441295B" section-type="undesignated-section">
      <enum/>
      <text>That it is the sense of the <cato:entity-ref entity-type="federal-body" entity-id="0050">House of
			 Representatives</cato:entity-ref> that the <cato:entity-ref entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> should exercise its
			 acknowledged authority toâ€”</text>
			<paragraph id="HEA3D222B07474BF5B042F57907A80D95">
        <enum>(1)</enum>
        <text>refuse to approve
			 generic versions of non-abuse-deterrent opioid products that have been replaced
			 in the market with abuse-deterrent formulations; and</text>
			</paragraph>
      <paragraph id="H596261FDCB6545F99FAE28830DF20CAC">
        <enum>(2)</enum>
        <text>require generic
			 versions of abuse-deterrent opioid products to be formulated with comparable
			 abuse-deterrent features.</text>
			</paragraph>
    </section>
  </resolution-body>
</resolution>
</doc>